Cosmo NVCMOPF +0.67%79 Net Current Asset Value is $3.83 as of Dec. 2025, which is 77% below its 10-year median of 16.96. GuruFocus rates CMOPF with a GF Score™ of 79/100 and a GF Value™ of $54.25 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 609 Drug Manufacturers companies, Cosmo NV ranks worse than 85.71% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Cosmo NV's net current asset value per share for the quarter that ended in Dec. 2025 was $3.83.
The historical rank and industry rank for Cosmo NV's Net Current Asset Value or its related term are showing as below:
CMOPF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.01 Med: 16.96 Max: 291.43
Current: 23.14
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Cosmo NV was 291.43. The lowest was 6.01. And the median was 16.96.
CMOPF's Price-to-Net-Current-Asset-Value is ranked worse than 85.71% of 609
companies
in the Drug Manufacturers industry
Industry Median: 5.72
vs CMOPF: 23.14
Cosmo NV (OTCPK:CMOPF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Cosmo NV Net Current Asset Value Related Terms
Cosmo NV Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Cosmo NV's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CMOPF vs LLY, JNJ, ABBV: Net Current Asset Value Comparison
For the Drug Manufacturers - General subindustry, Cosmo NV's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Cosmo NV's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $3.83 mean?
Cosmo NV (CMOPF) has a Net Current Asset Value of $3.83 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Cosmo NV and its competitors. This is 77% below median its historical median of 16.96. Over the past decade, Cosmo NV's Net Current Asset Value has ranged from 6.01 to 291.43. According to the industry distribution chart, Cosmo NV ranks #522 out of 609 companies in the Drug Manufacturers industry, placing it in the top 85.7%.
Is Cosmo NV's Net Current Asset Value too high?
Cosmo NV's current Net Current Asset Value of $3.83 is 77% below median its 10-year median of 16.96. Over the past 10 years, this metric has ranged from a low of 6.01 to a high of 291.43. The Drug Manufacturers industry median Net Current Asset Value is 5.72. Cosmo NV's value of $3.83 is 33% below this industry median. Based on the distribution chart, Cosmo NV ranks #522 out of 609 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cosmo NV has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's Net Current Asset Value compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #522 out of 609 companies for Net Current Asset Value. This places Cosmo NV in the lower half of its industry. The industry median Net Current Asset Value is 5.72. Cosmo NV's value of $3.83 is 33% below this benchmark. Historically, Cosmo NV's own Net Current Asset Value has ranged from 6.01 to 291.43 over the past decade. While the company's 10-year median is 16.96 vs. the industry median of 5.72, Cosmo NV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.72, based on 609 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo NV's current Net Current Asset Value of $3.83 is 33% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Cosmo NV and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current Net Current Asset Value is $3.83, which is 77% below median its own 10-year median of 16.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (CMOPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $54.25, compared to a current price of $82.60 — trading 52.3% above its estimated fair value. The current Net Current Asset Value is $3.83, which is 77% below median its 10-year median of 16.96 and 33% below the Drug Manufacturers industry median of 5.72. Cosmo NV's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Cosmo NV (CMOPF), the current Net Current Asset Value is $3.83 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (CMOPF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of $82.60 is trading 52.3% above its estimated GF Value™ of $54.25.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for CMOPF:
Net Current Asset Value: $3.83 (77% below median its 10-year median of 16.96)
GF Value™: $54.25 vs. price of $82.60 (52.3% above fair value)
Industry Position: 33% below the Drug Manufacturers median (#522 of 609)
No single metric tells the full story. See the CMOPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
79GF Score
Get the complete analysis for CMOPF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMOPF has been successfully added to your 
